Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 5, 2010, Pages 335-346

  Udyavar, Akshata ^a   Geiger, Terrence L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adoptive immunotherapy; Cancer; Gene therapy; T cell receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; MELAN A; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; TUMOR ANTIGEN; TYROSINE RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL THERAPY; CLINICAL TRIAL; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPH NODE METASTASIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NASOPHARYNX CARCINOMA; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; CELL GROWTH PROCESSES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 77956189220     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0090-1     Document Type: Review

References (166)

1. R Alli P Nguyen TL Geiger 2008 Retrogenic modeling of experimental allergic encephalomyelitis associates T cell frequency but not TCR functional affinity with pathogenicity J Immunol 181 136 145 18566378
2. A Amrani J Verdaguer P Serra, et al. 2000 Progression of autoimmune diabetes driven by avidity maturation of a T-cell population Nature 406 739 742 10963600
3. TP Arstila A Casrouge V Baron, et al. 1999 A direct estimate of the human alphabeta T cell receptor diversity Science 286 958 961 10542151
4. D Atanackovic Y Cao JW Kim, et al. 2008 The local cytokine and chemokine milieu within malignant effusions Tumour Biol 29 93 104 18515987
5. MF Avril P Charpentier A Margulis, et al. 1992 Regression of primary melanoma with metastases Cancer 69 1377 1381 1540876
6. C Badoual S Hans J Rodriguez, et al. 2006 Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers Clin Cancer Res 12 465 472 16428488
7. C Berger MC Jensen PM Lansdorp, et al. 2008 Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 294 305 18060041
8. H Bernhard J Neudorfer K Gebhard, et al. 2008 Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer Cancer Immunol Immunother 57 271 280 17646988
9. B Bierie HL Moses 2010 Transforming growth factor beta (TGF-beta) and inflammation in cancer Cytokine Growth Factor Rev 21 49 59 20018551
10. O Bilgi B Karagoz O Turken, et al. 2008 Peripheral blood gamma-delta T cells in advanced-stage cancer patients Adv Ther 25 218 224 18369538
11. RA Blades PJ Keating LJ McWilliam, et al. 1995 Loss of HLA class I expression in prostate cancer: Implications for immunotherapy Urology 46 681 687 7495121
12. DA Blair L Lefrancois 2007 Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells Proc Natl Acad Sci USA 104 15045 15050 17827281
13. CM Bollard L Aguilar KC Straathof, et al. 2004 Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease J Exp Med 200 1623 1633 15611290
14. A Boni P Muranski L Cassard, et al. 2008 Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers Blood 112 4746 4754 18799724
15. JM Boulter BK Jakobsen 2005 Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens Clin Exp Immunol 142 454 460 16297157
16. IE Brown M Mashayekhi M Markiewicz, et al. 2005 Peripheral survival of naïve CD8+ T cells Apoptosis 10 5 11 15711917
17. JD Bui RD Schreiber 2007 Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19 203 208 17292599
18. OL Caballero YT Chen 2009 Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Sci 100 2014 2021 19719775
19. AE Chang S Shu 1996 Current status of adoptive immunotherapy of cancer Crit Rev Oncol Hematol 22 213 228 8793276
20. AS Chervin DH Aggen JM Raseman, et al. 2008 Engineering higher affinity T cell receptors using a T cell display system J Immunol Methods 339 175 184 18854190
21. LK Chlewicki PD Holler BC Monti, et al. 2005 High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3 J Mol Biol 346 223 239 15663940
22. P Circosta L Granziero A Follenzi, et al. 2009 TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T-cells without prior stimulation of endogenous TCR Hum Gene Ther 29 1576 1588
23. CJ Cohen Y Zhao Z Zheng, et al. 2006 Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability Cancer Res 66 8878 8886 16951205
24. ME Connor PL Stern 1990 Loss of MHC class-I expression in cervical carcinomas Int J Cancer 46 1029 1034 2174412
25. H Conrad K Gebhard H Kronig, et al. 2008 CTLs directed against HER2 specifically cross-react with HER3 and HER4 J Immunol 180 8135 8145 18523278
26. LJ Cooper L Ausubel M Gutierrez, et al. 2006 Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma Cytotherapy 8 105 117 16698684
27. G Cui R Goll T Olsen, et al. 2007 Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum Cancer Immunol Immunother 56 985 995 17160410
28. TJ Curiel G Coukos L Zou, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 15322536
29. MG de Herve A Cariou F Simonetta, et al. 2008 Heterospecific CD4 help to rescue CD8 T cell killers J Immunol 181 5974 5980
30. F De Vita M Orditura G Galizia, et al. 1999 Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies Cancer 86 1936 1943 10570416
31. F De Vita M Orditura G Galizia, et al. 2000 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Chest 117 365 373 10669676
32. MA de Witte M Coccoris MC Wolkers, et al. 2006 Targeting self-antigens through allogeneic TCR gene transfer Blood 108 870 877 16861342
33. MA de Witte GM Bendle MD van den Boom, et al. 2008 TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation J Immunol 181 2563 2571 18684947
34. ML Disis 2009 Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment Clin Cancer Res 15 6476 6478 19861446
35. DL Donermeyer KS Weber DM Kranz, et al. 2006 The study of high-affinity TCRs reveals duality in T cell recognition of antigen: specificity and degeneracy J Immunol 177 6911 6919 17082606
36. ML Donnelly LE Hughes G Luke, et al. 2001 The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences J Gen Virol 82 1027 1041 11297677
37. ML Donnelly G Luke A Mehrotra, et al. 2001 Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip' J Gen Virol 82 1013 1025 11297676
38. ML Dossett RM Teague TM Schmitt, et al. 2009 Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR Mol Ther 17 742 749 19209146
39. ME Dudley SA Rosenberg 2007 Adoptive cell transfer therapy Semin Oncol 34 524 531 18083376
40. TJ Eberlein M Rosenstein P Spiess, et al. 1982 Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor Cancer Immunol Immunother 13 5 13 6984355
41. LM Ebert YC Liu CS Clements, et al. 2009 A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design Cancer Res 69 1046 1054 19176376
42. B Engels W Uckert 2007 Redirecting T lymphocyte specificity by T cell receptor gene transfer-a new era for immunotherapy Mol Aspects Med 28 115 142 17307249
43. M Fasso N Anandasabapathy F Crawford, et al. 2000 T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo J Exp Med 192 1719 1730 11120769
44. MJ Feito A Jimenez-Perianez G Ojeda, et al. 2002 The TCR/CD3 complex: molecular interactions in a changing structure Arch Immunol Ther Exp 50 263 272
45. RA Figlin JA Thompson RM Bukowski, et al. 1999 Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma J Clin Oncol 17 2521 2529 10561318
46. JA Freudenberg Q Wang M Katsumata, et al. 2009 The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies Exp Mol Pathol 87 1 11 19450579
47. G Galizia M Orditura C Romano, et al. 2002 Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery Clin Immunol 102 169 178 11846459
48. A Garcia-Lora I Algarra F Garrido 2003 MHC class I antigens, immune surveillance, and tumor immune escape J Cell Physiol 195 346 355 12704644
49. L Gattinoni DJ Powell Jr SA Rosenberg, et al. 2006 Adoptive immunotherapy for cancer: building on success Nat Rev Immunol 6 383 393 16622476
50. L Giacomelli W Gianni C Belfiore, et al. 2003 Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse Clin Cancer Res 9 2678 2682 12855647
51. L Gorelik RA Flavell 2001 Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat Med 7 1118 1122 11590434
52. GM Halliday A Patel MJ Hunt, et al. 1995 Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells World J Surg 19 352 358 7638987
53. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10647931
54. BJ Hare DF Wyss MS Osburne, et al. 1999 Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor Nat Struct Biol 6 574 581 10360364
55. MH Heemskerk 2006 Optimizing TCR gene transfer Clin Immunol 119 121 122 16503199
56. MH Heemskerk RS Hagedoorn MA van der Hoorn, et al. 2007 Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex Blood 109 235 243 16968899
57. HE Heslop KS Slobod MA Pule, et al. 2010 Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients Blood 115 925 935 19880495
58. CS Hinrichs ZA Borman L Cassard, et al. 2009 Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity Proc Natl Acad Sci USA 106 17469 17474 19805141
59. HH Hofstetter OS Targoni AY Karulin, et al. 2005 Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis? J Immunol 174 4598 4605 15814682
60. PD Holler DM Kranz 2003 Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation Immunity 18 255 264 12594952
61. PD Holler LK Chlewicki DM Kranz 2003 TCRs with high affinity for foreign pMHC show self-reactivity Nat Immunol 4 55 62 12469116
62. S Hong J Qian J Yang, et al. 2008 Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth Cancer Res 68 8456 8464 18922919
63. S Hori M Haury A Coutinho, et al. 2002 Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice Proc Natl Acad Sci USA 99 8213 8218 12034883
64. CS Hsieh Y Zheng Y Liang, et al. 2006 An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires Nat Immunol 7 401 410 16532000
65. MS Hughes YY Yu ME Dudley, et al. 2005 Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions Hum Gene Ther 16 457 472 15871677
66. NN Hunder H Wallen J Cao, et al. 2008 Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 N Engl J Med 358 2698 2703 18565862
67. EN Huter GH Stummvoll RJ DiPaolo, et al. 2008 Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease J Immunol 181 8209 8213 19050237
68. E Jäger M Ringhoffer M Altmannsberger, et al. 1997 Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma Int J Cancer 71 142 147 9139833
69. LA Johnson RA Morgan ME Dudley, et al. 2009 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 535 546 19451549
70. LL Jones LA Colf AJ Bankovich, et al. 2008 Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors Biochemistry 47 12398 12408 18973345
71. D Kabelitz D Wesch E Pitters, et al. 2004 Potential of human gammadelta T lymphocytes for immunotherapy of cancer Int J Cancer 112 727 732 15386388
72. T Kammertoens T Blankenstein 2009 Making and circumventing tolerance to cancer Eur J Immunol 39 2345 2353 19634191
73. RM Kedl JW Kappler P Marrack 2003 Epitope dominance, competition and T cell affinity maturation Curr Opin Immunol 15 120 127 12495743
74. B Klein ZY Lu ZJ Gu, et al. 1999 Interleukin-10 and Gp130 cytokines in human multiple myeloma Leuk Lymphoma 34 63 70 10350333
75. L Klein M Hinterberger G Wirnsberger, et al. 2009 Antigen presentation in the thymus for positive selection and central tolerance induction Nat Rev Immunol 9 833 844 19935803
76. J Kline IE Brown YY Zha, et al. 2008 Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma Clin Cancer Res 14 3156 3167 18483384
77. J Kuball ML Dossett M Wolfl, et al. 2007 Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2331 2338 17082316
78. DF Lake ML Salgaller P van der Bruggen, et al. 1999 Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1 Int Immunol 11 745 751 10330280
79. B Li AS Lalani TC Harding, et al. 2006 Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clin Cancer Res 12 6808 6816 17121902
80. L Li QG Chao LZ Ping, et al. 2009 The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC Cancer Biother Radiopharm 24 357 367 19538059
81. G Liu K Yao B Wang, et al. 2009 Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein Cell Mol Immunol 6 423 431 20003818
82. X Liu P Nguyen W Liu, et al. 2009 T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3+ regulatory T cells Immunity 31 909 920 20005134
83. UK Liyanage TT Moore H-G Joo, et al. 2002 Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 2756 2761 12193750
84. S Lob A Konigsrainer HG Rammensee, et al. 2009 Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9 445 452 19461669
85. M Lotze A Chang C Seipp 1986 High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer JAMA 256 3117 3124 3491225
86. L Malherbe C Hausl L Teyton, et al. 2004 Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties Immunity 21 669 679 15539153
87. P Marrack JP Scott-Browne S Dai, et al. 2008 Evolutionarily conserved amino acids that control TCR-MHC interaction Annu Rev Immunol 26 171 203 18304006
88. N Martin-Orozco P Muranski Y Chung, et al. 2009 T helper 17 cells promote cytotoxic T cell activation in tumor immunity Immunity 31 787 798 19879162
89. TA Moo-Young JW Larson BA Belt, et al. 2009 Tumor-derived TGF-beta mediates conversion of CD4+ Foxp3+ regulatory T cells in a murine model of pancreas cancer J Immunother 32 12 21 19307989
90. RA Morgan ME Dudley Y Yu, et al. 2003 High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens J Immunol 171 3287 3295 12960359
91. RA Morgan ME Dudley JR Wunderlich, et al. 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126 129 16946036
92. J Mule S Shu S Schwarz, et al. 1984 Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 225 1487 1489 6332379
93. P Muranski NP Restifo 2009 Adoptive immunotherapy of cancer using CD4(+) T cells Curr Opin Immunol 21 200 208 19285848
94. Y Nakanishi B Lu C Gerard, et al. 2009 CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help Nature 462 510 513 19898495
95. M Nakui A Ohta M Sekimoto, et al. 2000 Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells Clin Exp Metastasis 18 147 153 11235990
96. Y Nesbeth U Scarlett J Cubillos-Ruiz, et al. 2009 CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion Cancer Res 69 6331 6338 19602595
97. T Nicholaou L Ebert ID Davis, et al. 2006 Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1 Immunol Cell Biol 84 303 317 16681828
98. T Nishimura H Kitamura K Iwakabe, et al. 2000 The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes Int Immunol 12 987 994 10882410
99. P Norris E Rosenberg 2002 CD4+ T helper cells and the role they play in viral control J Mol Med 80 397 405 12110945
100. S Okamoto J Mineno H Ikeda, et al. 2009 Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR Cancer Res 69 9003 9011 19903853
101. WW Overwijk DS Lee DR Surman, et al. 1999 Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes Proc Natl Acad Sci USA 96 2982 2987 10077623
102. DC Palmer C-C Chan L Gattinoni, et al. 2008 Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity Proc Natl Acad Sci USA 105 8061 8066 18523011
103. DM Pardoll SL Topalian 1998 The role of CD4+ T cell responses in antitumor immunity Curr Opin Immunol 10 588 594 9794842
104. KS Peggs SA Quezada CA Chambers, et al. 2009 Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies J Exp Med 206 1717 1725 19581407
105. PD Peng CJ Cohen S Yang, et al. 2009 Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity Gene Ther 16 1042 1049 19494842
106. U Petrausch SM Jensen C Twitty, et al. 2009 Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity J Immunol 183 3682 3689 19692636
107. GQ Phan CE Touloukian JC Yang, et al. 2003 Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens J Immunother 26 349 356 12843797
108. GQ Phan JC Yang RM Sherry, et al. 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 100 8372 8377 12826605
109. K Pike-Overzet M van der Burg G Wagemaker, et al. 2007 New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy Mol Ther 15 1910 1916 17726455
110. CH Poehlein DP Haley EB Walker, et al. 2009 Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts Eur J Immunol 39 3121 3133 19839008
111. DJ Powell M Dudley P Robbins, et al. 2005 Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy Blood 105 241 250 15345595
112. KD Preuss C Zwick C Bormann, et al. 2002 Analysis of the B-cell repertoire against antigens expressed by human neoplasms Immunol Rev 188 43 50 12445280
113. DA Price JM Brenchley LE Ruff, et al. 2005 Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses J Exp Med 202 1349 1361 16287711
114. MA Pule B Savoldo GD Myers, et al. 2008 Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 1264 1270 18978797
115. I Radtke CG Mullighan M Ishii, et al. 2009 Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia Proc Natl Acad Sci USA 106 12944 12949 19651601
116. W Rees J Bender TK Teague, et al. 1999 An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro Proc Natl Acad Sci USA 96 9781 9786 10449771
117. SA Richman DM Kranz 2007 Display, engineering, and applications of antigen-specific T cell receptors Biomol Eng 24 361 373 17409021
118. LM Rimsza RA Roberts TP Miller, et al. 2004 Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project Blood 103 4251 4425 14976040
119. PF Robbins YF Li M El-Gamil, et al. 2008 Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions J Immunol 180 6116 6131 18424733
120. SA Rosenberg 1999 A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity 10 281 287 10204484
121. SA Rosenberg JC Yang RM Sherry, et al. 2003 Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Hum Gene Ther 14 709 714 12804135
122. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 15340416
123. SA Rosenberg NP Restifo JC Yang, et al. 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 299 308 18354418
124. JE Rubnitz H Inaba RC Ribeiro, et al. 2010 NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 955 959 20085940
125. TM Schmitt GB Ragnarsson PD Greenberg 2009 TCR gene therapy for cancer Hum Gene Ther 20 1240 1248 19702439
126. Z Sebestyen E Schooten T Sals, et al. 2008 Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer J Immunol 180 7736 7746 18490778
127. Selvaraj RK, Geiger TL (2007) A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol 179:11 p following 1390
128. RK Selvaraj TL Geiger 2008 Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance J Immunol 180 2830 2838 18292504
129. KA Shafer-Weaver MJ Anderson K Stagliano, et al. 2009 Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells J Immunol 183 4848 4852 19801511
130. KA Shafer-Weaver SK Watkins MJ Anderson, et al. 2009 Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells Cancer Res 69 6256 6264 19622771
131. V Shankaran H Ikeda AT Bruce, et al. 2001 IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107 1111 11323675
132. MJ Smyth GP Dunn RD Schreiber 2006 Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 1 50 16730260
133. B Stockinger M Veldhoen 2007 Differentiation and function of Th17 T cells Curr Opin Immunol 19 281 286 17433650
134. JD Stone AS Chervin DM Kranz 2009 T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity Immunology 126 165 176 19125887
135. H Suzuki H Onishi J Wada, et al. 2010 VEGFR2 is selectively expressed by FOXP3(high)CD4(+) regulatory T cells Eur J Immunol 40 197 203 19902430
136. AL Szymczak CJ Workman Y Wang, et al. 2004 Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector Nat Biotechnol 22 589 594 15064769
137. Q Tang KJ Henriksen M Bi EB Finger, et al. 2004 In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes J Exp Med 199 1455 1465 15184499
138. M Terabe S Matsui N Noben-Trauth, et al. 2000 NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nat Immunol 1 515 520 11101874
139. M Theobald J Biggs J Hernández, et al. 1997 Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes J Exp Med 185 833 841 9120389
140. A Udyavar R Alli P Nguyen, et al. 2009 Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity J Immunol 182 4439 4447 19299745
141. L Varani AJ Bankovich CW Liu, et al. 2007 Solution mapping of T cell receptor docking footprints on peptide-MHC Proc Natl Acad Sci USA 104 13080 13085 17670943
142. A Varela-Rohena BK Jakobsen AK Sewell, et al. 2009 Are affinity-enhanced T cells the future of HIV therapy? HIV Ther 3 105 108
143. JW Verbsky 2007 Therapeutic use of T regulatory cells Curr Opin Rheumatol 19 252 258 17414951
144. R-H Voss J Kuball R Engel, et al. 2006 Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression Immunol Res 34 67 87 16720899
145. RH Voss RA Willemsen J Kuball, et al. 2008 Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells J Immunol 180 391 401 18097040
146. R-F Wang 2001 The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity Trends Immunol 22 269 276 11323286
147. M Warabi M Kitagawa K Hirokawa 2000 Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas Pathol Res Pract 196 807 815 11156321
148. JA Wargo PF Robbins Y Li, et al. 2009 Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression Cancer Immunol Immunother 58 383 394 18677478
149. J Weber 2007 Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events Oncologist 12 864 872 17673617
150. KS Weber DL Donermeyer PM Allen, et al. 2005 Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function Proc Natl Acad Sci USA 102 19033 19038 16365315
151. DB Wilson DH Wilson K Schroder, et al. 2004 Specificity and degeneracy of T cells Mol Immunol 40 1047 1055 15036909
152. SB Wong R Bos LA Sherman 2008 Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells J Immunol 180 3122 3131 18292535
153. CJ Workman AL Szymczak-Workman LW Collison, et al. 2009 The development and function of regulatory T cells Cell Mol Life Sci 66 2603 2622 19390784
154. GP Wright CA Notley SA Xue, et al. 2009 Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis Proc Natl Acad Sci USA 106 19078 19083 19884493
155. SH Wrzesinski YY Wan RA Flavell 2007 Transforming growth factor-beta and the immune response: implications for anticancer therapy Clin Cancer Res 13 5262 5270 17875754
156. JJ Xu K Yao CJ Yu, et al. 2006 Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells Auris Nasus Larynx 33 441 446 16934422
157. C Yee JA Thompson P Roche, et al. 2000 Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo J Exp Med 192 1637 1643 11104805
158. Yeh S, Karne NK, Kerkar SP et al. (2009) Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116:981-989.e1
159. P Yu Y-X Fu 2006 Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86 231 245 16446705
160. FY Yue R Dummer R Geertsen, et al. 1997 Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules Int J Cancer 71 630 637 9178819
161. T Zhang X He TC Tsang, et al. 2004 Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function Cancer Gene Ther 11 487 496 15153936
162. Y Zhang D Wakita K Chamoto, et al. 2007 Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs Int Immunol 19 151 161 17189593
163. S Zhang H Zhang J Zhao 2009 The role of CD4 T cell help for CD8 CTL activation Biochem Biophys Res Commun 384 405 408 19410556
164. Y Zhao AD Bennett Z Zheng, et al. 2007 High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines J Immunol 179 5845 5854 17947658
165. X Zhou Y Cui X Huang, et al. 2003 Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells Hum Gene Ther 14 089 1105
166. W Zou 2005 Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 63 274